Two Cases of Idiopathic Multicentric Castleman Disease with Nephrotic Syndrome Treated with Tocilizumab

Overview

Journal CEN Case Rep

Specialty Nephrology

Date 2020 Jul 28

PMID 32715375

Citations 6

Authors

Norihiro Furutera

Naoya Fukunaga

Jun Okita

Tomoko Suzuki

Yuko Suenaga

Yuzo Oyama

Kohei Aoki

Akihiro Fukuda

Takeshi Nakata

Noriko Uesugi

Tsutomu Daa

Satoshi Hisano

Hirotaka Shibata

Affiliations

Soon will be listed here.

Abstract

We report two cases of idiopathic multicentric Castleman disease (iMCD) with nephrotic syndrome (NS) treated with tocilizumab. Case 1 was a 58-year-old man diagnosed with iMCD prior to the onset of NS. Renal biopsy revealed membranous nephropathy, which was considered to be secondary membranous nephropathy associated with iMCD. Case 2 was a 49-year-old woman diagnosed with iMCD prior to NS. Renal biopsy revealed renal amyloidosis positive for Congo red staining and amyloid A protein immunostaining. In both the cases, the proteinuria improved after the initiation of glucocorticoid and tocilizumab therapy. Tocilizumab may be a good therapeutic choice for iMCD with NS.

Citing Articles

The Role of Cytokines and Chemokines as Biomarkers of Disease Activity in Idiopathic Nephrotic Syndrome in Children.

Kopac M, Jerin A, Petrera A, Osredkar J Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996798 PMC: 11854277. DOI: 10.3390/cimb47020077.

A Case of Castleman's Disease during the Long-Term Course of Membranous Nephropathy.

Nakajima S, Nagai K, Sakata A, Usui J, Yamagata K, Ueda A Case Rep Nephrol. 2023; 2023:4926000.

PMID: 36873956 PMC: 9977547. DOI: 10.1155/2023/4926000.

Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series.

Kojima D, Yamaguchi S, Hashiguchi A, Hayashi K, Uchiyama K, Yoshimoto N Front Med (Lausanne). 2023; 9:1037032.

PMID: 36698794 PMC: 9868391. DOI: 10.3389/fmed.2022.1037032.

Recovery from AA amyloidosis-cardiomyopathy complexed with unicentric Castleman disease.

Imamura K, Kojima S, Imamura T, Tsujita K BMJ Case Rep. 2022; 15(8).

PMID: 35981748 PMC: 9394191. DOI: 10.1136/bcr-2022-250338.

Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.

Saiki R, Katayama K, Hirabayashi Y, Oda K, Fujimoto M, Murata T BMC Nephrol. 2021; 22(1):216.

PMID: 34107915 PMC: 8191014. DOI: 10.1186/s12882-021-02423-w.

References

Yamada Y, Ueno T, Irifuku T, Nakashima A, Doi S, Ichinohe T . Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report . Clin Nephrol. 2018; 90(3):232-236. DOI: 10.5414/CN109273. View

van Rhee F, Greenway A, Stone K . Treatment of Idiopathic Castleman Disease. Hematol Oncol Clin North Am. 2017; 32(1):89-106. DOI: 10.1016/j.hoc.2017.09.008. View

Imai H, Hamai K, Komatsuda A, Ohtani H, Miura A . IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int. 1997; 51(1):270-6. DOI: 10.1038/ki.1997.32. View

Liu L, Chang B, Wu X, Guo Y, Pan Y, Yang L . Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy. Vasc Health Risk Manag. 2018; 14:103-108. PMC: 5983022. DOI: 10.2147/VHRM.S160883. View

Hakroush S, Moeller M, Theilig F, Kaissling B, Sijmonsma T, Jugold M . Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am J Pathol. 2009; 175(5):1883-95. PMC: 2774053. DOI: 10.2353/ajpath.2009.080792. View

Maeshima A, Nakasatomi M, Henmi D, Yamashita S, Kaneko Y, Kuroiwa T . Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease. CEN Case Rep. 2017; 1(1):7-11. PMC: 5387888. DOI: 10.1007/s13730-012-0004-7. View

KELLER A, Hochholzer L, Castleman B . Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972; 29(3):670-83. DOI: 10.1002/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-#. View

Fajgenbaum D . Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood. 2018; 132(22):2323-2330. PMC: 6265649. DOI: 10.1182/blood-2018-05-848671. View

Jones S, Fraser D, Fielding C, Jones G . Interleukin-6 in renal disease and therapy. Nephrol Dial Transplant. 2014; 30(4):564-74. DOI: 10.1093/ndt/gfu233. View

10.

Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K . IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004; 314(2):363-9. DOI: 10.1016/j.bbrc.2003.12.096. View

11.

Liu A, Nabel C, Finkelman B, Ruth J, Kurzrock R, van Rhee F . Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016; 3(4):e163-75. DOI: 10.1016/S2352-3026(16)00006-5. View

12.

van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M . International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018; 132(20):2115-2124. PMC: 6238190. DOI: 10.1182/blood-2018-07-862334. View

13.

Xu D, Lv J, Dong Y, Wang S, Su T, Zhou F . Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant. 2011; 27 Suppl 3:iii119-25. DOI: 10.1093/ndt/gfr245. View

14.

Hayashi N, Akiyama S, Okuyama H, Matsui Y, Adachi H, Yamaya H . Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese. Clin Exp Nephrol. 2014; 19(5):797-803. DOI: 10.1007/s10157-014-1064-0. View

15.

Liu Y, Stone K, van Rhee F . Siltuximab for multicentric Castleman disease. Expert Rev Hematol. 2014; 7(5):545-57. DOI: 10.1586/17474086.2014.946402. View

16.

Castleman B, IVERSON L, MENENDEZ V . Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956; 9(4):822-30. DOI: 10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4. View

17.

Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T . Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop. 2013; 53(1):69-77. DOI: 10.3960/jslrt.53.69. View

18.

Furuichi K, Wada T, Shimizu M, Segawa C, Ohta S, Takasawa K . Antimyeloperoxidase-antibody-positive rapidly progressive glomerulonephritis associated with Castleman's disease. Nephrol Dial Transplant. 1998; 13(6):1556-8. DOI: 10.1093/ndt/13.6.1556. View

19.

Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K . Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989; 74(4):1360-7. View

20.

Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S . Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005; 106(8):2627-32. DOI: 10.1182/blood-2004-12-4602. View